CA3072329A1 - Plate-forme de generation d'agents therapeutiques cellulaires sans risque - Google Patents

Plate-forme de generation d'agents therapeutiques cellulaires sans risque Download PDF

Info

Publication number
CA3072329A1
CA3072329A1 CA3072329A CA3072329A CA3072329A1 CA 3072329 A1 CA3072329 A1 CA 3072329A1 CA 3072329 A CA3072329 A CA 3072329A CA 3072329 A CA3072329 A CA 3072329A CA 3072329 A1 CA3072329 A1 CA 3072329A1
Authority
CA
Canada
Prior art keywords
therapeutic
cell
cytoplasts
cytoplast
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3072329A
Other languages
English (en)
Inventor
Huawei Wang
Richard Klemke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of CA3072329A1 publication Critical patent/CA3072329A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • C12N2509/10—Mechanical dissociation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2513/00—3D culture

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)

Abstract

L'invention concerne des cytoplastes, des compositions comportant des cytoplastes, des méthodes d'utilisation des cytoplastes, et des méthodes de traitement de sujets, telles que l'apport de bienfaits à un sujet sain ou malade, ou de traitement ou de diagnostic d'une maladie ou d'un état pathologique chez un sujet. Dans certains modes de réalisation, les méthodes de traitement d'un sujet comprennent : l'administration au sujet d'une quantité thérapeutiquement efficace d'une composition comportant un cytoplaste. L'invention concerne également des compositions (par exemple des compositions pharmaceutiques) qui comprennent un cytoplaste. L'invention concerne également des nécessaires comprenant des instructions pour utiliser les compositions ou les méthodes.
CA3072329A 2017-08-07 2018-08-07 Plate-forme de generation d'agents therapeutiques cellulaires sans risque Pending CA3072329A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762542133P 2017-08-07 2017-08-07
US62/542,133 2017-08-07
PCT/US2018/045686 WO2019032628A1 (fr) 2017-08-07 2018-08-07 Plate-forme de génération d'agents thérapeutiques cellulaires sans risque

Publications (1)

Publication Number Publication Date
CA3072329A1 true CA3072329A1 (fr) 2019-02-14

Family

ID=65271704

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3072329A Pending CA3072329A1 (fr) 2017-08-07 2018-08-07 Plate-forme de generation d'agents therapeutiques cellulaires sans risque

Country Status (9)

Country Link
US (8) US20200368285A1 (fr)
EP (1) EP3664830A4 (fr)
JP (2) JP2020530454A (fr)
KR (2) KR20200037353A (fr)
CN (1) CN111491655A (fr)
AU (1) AU2018316166A1 (fr)
CA (1) CA3072329A1 (fr)
GB (2) GB2578394A (fr)
WO (1) WO2019032628A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018316166A1 (en) * 2017-08-07 2020-02-06 The Regents Of The University Of California Platform for generating safe cell therapeutics
US10960071B2 (en) * 2017-08-07 2021-03-30 The Regents Of The University Of California Platform for generating safe cell therapeutics
GB2590302B (en) 2018-07-06 2023-03-22 The Regents Of The Univ Of Colorado A Body Corporate Existing Under The Laws Of The State Of Colorad Genetically encoded system for constructing and detecting biologically active agents
CA3169984A1 (fr) * 2020-02-07 2021-08-12 The Regents Of The University Of California Methodes et utilisation pour la modification genetique de cellules enucleees
JP2023515355A (ja) * 2020-02-11 2023-04-13 サイトナス セラピューティクス，インク． 高速ワクチンプラットフォーム

Family Cites Families (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1010543A (en) 1911-05-04 1911-12-05 George A Walter Drinking-fount.
US6538121B1 (en) 1994-11-01 2003-03-25 Human Genome Sciences, Inc. Interleukin-1 β converting enzyme like apoptosis protease-3 and 4
GB9514368D0 (en) 1995-07-13 1995-09-13 Medical Res Council Improvements in or relating to binding assays
US5811407A (en) 1997-02-19 1998-09-22 The University Of North Carolina At Chapel Hill System for the in vivo delivery and expression of heterologous genes in the bone marrow
US6511967B1 (en) 1999-04-23 2003-01-28 The General Hospital Corporation Use of an internalizing transferrin receptor to image transgene expression
US20110171185A1 (en) 1999-06-30 2011-07-14 Klimanskaya Irina V Genetically intact induced pluripotent cells or transdifferentiated cells and methods for the production thereof
US20040214783A1 (en) 2002-05-08 2004-10-28 Terman David S. Compositions and methods for treatment of neoplastic disease
US20100158871A1 (en) * 1999-08-30 2010-06-24 David Stephen Terman Sickled erythrocytes with antitumor molecules induce tumoricidal effects
US8071072B2 (en) 1999-10-08 2011-12-06 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
DE10003241A1 (de) 2000-01-26 2001-08-02 Werner Lubitz Verschließen von Bakterienghosts
AU9307501A (en) 2000-09-22 2002-04-02 Virxsys Improved conditionally replicating vectors, methods for their production and use
US20020142397A1 (en) * 2000-12-22 2002-10-03 Philippe Collas Methods for altering cell fate
DE10157475A1 (de) 2001-11-23 2003-06-18 Hans-Hermann Gerdes Verfahren und Mittel zur Beeinflussung von interzellulärer Kommunikation und interzellulären Organellentransport
US20030113910A1 (en) * 2001-12-18 2003-06-19 Mike Levanduski Pluripotent stem cells derived without the use of embryos or fetal tissue
KR101455222B1 (ko) 2002-12-16 2014-10-31 글로브이뮨 면역 요법으로서의 효모계 백신
US20060140963A1 (en) 2003-04-14 2006-06-29 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of CD59
US20040259249A1 (en) * 2003-05-16 2004-12-23 Nikolai Strelchenko Method of making stem cells from differentiated cells
WO2006055024A2 (fr) * 2004-04-05 2006-05-26 Vaxiion Therapeutics, Inc. Minicellules employees comme vaccins
WO2006096815A2 (fr) 2005-03-09 2006-09-14 Board Of Regents, The University Of Texas System Promoteur htmc et vecteurs destines a l'expression hautement efficace et selective pour une tumeur de genes therapeutiques contre le cancer
FR2919804B1 (fr) 2007-08-08 2010-08-27 Erytech Pharma Composition et vaccin therapeutique anti-tumoral
FR2928926B1 (fr) 2008-03-18 2015-08-21 Centre Nat Rech Scient Polynucleotides et polypeptides chimeriques permettant la secretion d'un polypeptide d'interet en association avec des exosomes et leur utilisation pour la production de compositions immunogenes
US20110070153A1 (en) 2008-08-13 2011-03-24 Searete, Llc, A Limited Liability Corporation Of The State Of Delaware Artificial cells
KR101781966B1 (ko) * 2009-04-17 2017-09-27 글로브이뮨 암에 대한 병용 면역요법 조성물 및 방법
GB201020738D0 (en) 2010-12-07 2011-01-19 Affitech Res As Antibodies
FI20115914L (fi) 2011-09-16 2013-03-17 Oncos Therapeutics Ltd Muunnettu onkolyyttinen virus
CN104822384A (zh) 2012-03-30 2015-08-05 南加州大学 用于间充质干细胞诱导的免疫调节的组合物和治疗方法
SG11201407239SA (en) 2012-05-09 2014-12-30 Gradalis Inc BI-FUNCTIONAL SHORT-HAIRPIN RNA (BI-SHRNA) SPECIFIC FOR SINGLE-NUCLEOTIDE <i>KRAS</i> MUTATIONS
EP3335721A1 (fr) 2013-04-12 2018-06-20 Evox Therapeutics Limited Vésicules d'administration thérapeutique
AU2014262474B2 (en) * 2013-05-10 2019-10-31 Whitehead Institute For Biomedical Research In vitro production of red blood cells with sortaggable proteins
EP3004357A4 (fr) 2013-06-04 2017-01-11 The Johns Hopkins University Expression en surface del'avidine/streptavidine, médiée par peg-prom
CA2915882C (fr) 2013-06-27 2022-12-06 Monash University Proteines de liaison il-21 et leurs utilisations
PT3027738T (pt) 2013-08-01 2022-05-11 Swedish Stromabio Ab Mscs no tratamento de doenças pulmonares inflamatórias
AU2014319921A1 (en) 2013-09-11 2016-03-17 Compugen Ltd. Anti-VSTM5 antibodies and the use thereof in therapy and diagnosis
CA2930665A1 (fr) * 2013-11-18 2015-05-21 Rubius Therapeutics, Inc. Complexes membrane synthetique- recepteur
AU2014352749A1 (en) 2013-11-22 2016-06-09 Dnatrix, Inc. Adenovirus expressing immune cell stimulatory receptor agonist(s)
WO2015128492A1 (fr) 2014-02-28 2015-09-03 Maghazachi Azzam A Monométhylfuramate et diméthylfumarate pour l'activation de cellules tueuses naturelles
CN106456744A (zh) * 2014-04-01 2017-02-22 鲁比厄斯治疗法股份有限公司 用于免疫调节的方法和组合物
JP2017515509A (ja) 2014-05-16 2017-06-15 イエール ユニバーシティ ワクチン用途のための高力価ウイルス様ベシクルの進化の方法
BR112017003582B1 (pt) 2014-08-27 2024-01-09 Memorial Sloan Kettering Cancer Center Agente de anticorpo, uso do mesmo, composição farmacêutica e receptor de antígeno quimérico
AU2015318233B2 (en) 2014-09-15 2020-03-12 Plexxikon Inc. Heterocyclic compounds and uses thereof
WO2016065330A1 (fr) 2014-10-24 2016-04-28 Aladar Szalay Technique d'immunotherapie combinee pour le traitement du cancer
US20160166613A1 (en) 2014-12-15 2016-06-16 Bellicum Pharmaceuticals, Inc. Methods for controlled elimination of therapeutic cells
WO2016141357A1 (fr) 2015-03-05 2016-09-09 Fred Hutchinson Cancer Research Center Protéines de fusion immunomodulatrices et leurs utilisations
EP3064507A1 (fr) 2015-03-06 2016-09-07 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Protéines de fusion comprenant une protéine de liaison et un polypeptide interleukine-15 ayant une affinité réduite pour IL15ra et leurs utilisations thérapeutiques
WO2016149559A1 (fr) 2015-03-18 2016-09-22 Aladar Szalay Virothérapie basée sur une combinaison d'anticorps
WO2016183482A1 (fr) * 2015-05-13 2016-11-17 Rubius Therapeutics, Inc. Agents thérapeutiques d'un complexe membrane-récepteur
KR101714695B1 (ko) 2015-05-18 2017-03-09 한국과학기술연구원 가교화된 pva-ecm 복합체를 제조하는 방법 및 그에 의하여 제조된 pva-ecm 복합체
CN104877965B (zh) * 2015-05-27 2018-04-20 上海厚东生物科技有限公司 一种制备成熟红细胞的方法
CN108135996B (zh) 2015-08-11 2022-06-21 卡利迪生物治疗有限公司 用以癌症治疗的天花疫苗
NZ741112A (en) 2015-09-21 2021-07-30 Plexxikon Inc Heterocyclic compounds and uses thereof
WO2017054085A1 (fr) 2015-10-01 2017-04-06 University Of Ottawa Encapsulation d'acides nucléiques dans des exosomes
PE20181515A1 (es) 2015-12-04 2018-09-21 Boehringer Ingelheim Int Polipeptidos biparatopicos que antagonizan la senalizacion wnt en celulas tumorales
CN117402829A (zh) 2015-12-14 2024-01-16 贝里坤制药股份有限公司 用于治疗性细胞活化或消除的双重控制
LT3402491T (lt) 2016-01-11 2022-02-25 Rubius Therapeutics, Inc. Kompozicijos ir būdai, susiję su daugiamodalinėmis terapinėmis ląstelių sistemomis, skirti vėžio indikacijoms
US10940199B2 (en) 2016-03-09 2021-03-09 Wisconsin Alumni Research Foundation Versikine for inducing and potentiating an immune response
IL261713B2 (en) 2016-03-19 2023-09-01 F1 Oncology Inc Methods and preparations for the transfer of lymphocytes and their regulated expansion
MX2021012977A (es) 2016-03-24 2022-10-03 Cothera Biosciences Inc Tratamiento del cáncer con tg02.
US11458097B2 (en) 2016-03-30 2022-10-04 The University Of North Carolina At Chapel Hill Biological agent-exosome compositions and uses thereof
EP3246410A1 (fr) 2016-05-19 2017-11-22 Klinikum rechts der Isar der Technischen Universität München Virus hybride vsv/vmn pour la thérapie du cancer oncolytique
GB201609216D0 (en) 2016-05-25 2016-07-06 Evox Therapeutics And Isis Innovation Ltd Exosomes comprising therapeutic polypeptides
US11090344B2 (en) 2016-05-27 2021-08-17 Dnatrix, Inc. Adenovirus and immunomodulator combination therapy
US11427625B2 (en) 2016-06-14 2022-08-30 University of Pittsburgh—of the Commonwealth System of Higher Education Expression of NKG2D activating ligand proteins for sensitizing cancer cells to attack by cytotoxic immune cells
CN107586341A (zh) 2016-07-08 2018-01-16 生命序有限公司 重组免疫检查点受体及免疫检查点抑制分子的共表达及应用
GB2552473A (en) 2016-07-21 2018-01-31 Evox Therapeutics Ltd Surface decoration of extracellular vesicles
CN116478290A (zh) 2016-08-26 2023-07-25 百济神州有限公司 抗tim-3抗体及其用途
US11583516B2 (en) 2016-09-07 2023-02-21 Trustees Of Tufts College Dash inhibitors, and uses related thereto
WO2018064513A1 (fr) 2016-09-30 2018-04-05 The Brigham And Women's Hospital, Inc. Virus oncolytiques codant des protéines d'évasion des cellules tueuses naturelles
US11084859B2 (en) 2016-10-24 2021-08-10 Orionis Biosciences BV Targeted mutant interferon-gamma and uses thereof
WO2018081738A1 (fr) 2016-10-28 2018-05-03 Children's Hospital Medical Center Traitement de maladies associées à irak activé
KR20190091497A (ko) 2016-12-02 2019-08-06 루비우스 테라퓨틱스, 아이엔씨. 고형 종양으로의 침투를 위한 세포 시스템과 관련된 조성물 및 방법
WO2018112033A1 (fr) 2016-12-13 2018-06-21 President And Fellows Of Harvard College Méthodes et compositions pour le ciblage de tregs infiltrant les tumeurs
US11617771B2 (en) 2016-12-15 2023-04-04 The Regents Of The University Of California Oral composition comprising lactic acid bacteria for regulating immune responses and methods related thereto
US11459378B2 (en) 2017-01-30 2022-10-04 Ohio State Innovation Foundation Passive antibody dependent cell-mediated activation
WO2018148378A1 (fr) 2017-02-08 2018-08-16 Dana-Farber Cancer Institute, Inc. Modulation de biomarqueurs pour accroître l'immunité antitumorale et améliorer l'efficacité d'une immunothérapie anticancéreuse
US20200276318A1 (en) 2017-03-06 2020-09-03 University Of Washington Engineered cells and agent compositions for therapeutic agent delivery and treatments using same
CN108623686A (zh) 2017-03-25 2018-10-09 信达生物制药(苏州)有限公司 抗ox40抗体及其用途
WO2018183479A1 (fr) 2017-03-30 2018-10-04 Dana-Farber Cancer Institute, Inc. Procédés de modulation de lymphocytes t régulateurs et de réponses immunitaires à l'aide d'inhibiteurs cdk4/6
US11026990B2 (en) 2017-04-12 2021-06-08 Shenzhen International Institute For Biomedical Research PUM 1 protein as target for virus inhibition
CN110621306A (zh) 2017-04-21 2019-12-27 科斯塔治疗公司 膜脂包被纳米颗粒及其使用方法
US11576872B2 (en) * 2017-05-08 2023-02-14 Flagship Pioneering Innovations V, Inc. Compositions for facilitating membrane fusion and uses thereof
SI3621694T1 (sl) 2017-05-09 2023-10-30 Scholar Rock, Inc Zaviralci lrrc33 in njihove uporabe
US11433143B2 (en) 2017-05-18 2022-09-06 The Regents Of The University Of California Nano-enabled immunotherapy in cancer
JP7522426B2 (ja) 2017-05-25 2024-07-25 ユニバーシティ オブ セントラル フロリダ リサーチ ファウンデーション，インコーポレイテッド 天然キラー細胞による殺傷に対する腫瘍細胞の感受性を高めるための新規な腫瘍溶解性ウイルス
MY200744A (en) 2017-05-31 2024-01-13 Boehringer Ingelheim Int Polypeptides antagonizing wnt signaling in tumor cells
US20210139846A1 (en) 2017-06-02 2021-05-13 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Engineered cells, and methods of using the same
US11820822B2 (en) 2017-06-06 2023-11-21 Dana-Farber Cancer Institute, Inc. Methods for sensitizing cancer cells to T cell-mediated killing by modulating molecular pathways
US11692172B2 (en) 2017-06-26 2023-07-04 Mackay Memorial Hosptal Formulation comprising extracellular vesicles, method for producing the same, and uses thereof
WO2019014665A1 (fr) 2017-07-14 2019-01-17 Dana-Farber Cancer Institute, Inc. Modulation de biomarqueurs pour accroître l'immunité antitumorale et améliorer l'efficacité d'une immunothérapie anticancéreuse
EP3654991A1 (fr) * 2017-07-19 2020-05-27 Rubius Therapeutics, Inc. Compositions et méthodes associées à des systèmes cellulaires thérapeutiques multimodaux pour le traitement d'une maladie infectieuse
AU2018316166A1 (en) * 2017-08-07 2020-02-06 The Regents Of The University Of California Platform for generating safe cell therapeutics
US10960071B2 (en) 2017-08-07 2021-03-30 The Regents Of The University Of California Platform for generating safe cell therapeutics
CN111511762A (zh) 2017-08-21 2020-08-07 天演药业公司 抗cd137分子及其用途
JP7365704B2 (ja) 2017-09-05 2023-10-20 グラディエーター バイオサイエンシーズ インコーポレイテッド 幹細胞へのペイロードの送達
GB201714430D0 (en) 2017-09-07 2017-10-25 Micol Romain Compositions and processes for targeted delivery and expression and modulation of therapeutic components in tissue
WO2019055851A1 (fr) 2017-09-15 2019-03-21 Nantomics, Llc Arn de hmgb1 et méthodes associées
WO2019060980A1 (fr) 2017-09-27 2019-04-04 University Of Ottawa Particules virales enveloppées fluorescentes en tant que références pour la cytométrie en flux nanométrique
JP2020535160A (ja) 2017-09-28 2020-12-03 タンデム カンパニー，リミテッド 癌治療用の新規な組換え原形質膜をベースとする小胞体
US20210040205A1 (en) 2017-10-25 2021-02-11 Novartis Ag Antibodies targeting cd32b and methods of use thereof
WO2019090148A2 (fr) 2017-11-03 2019-05-09 Rubius Therapeutics, Inc. Compositions et procédés associés à des systèmes cellulaires thérapeutiques pour inhiber la croissance tumorale
WO2019090355A1 (fr) 2017-11-06 2019-05-09 Children's National Medical Center Cellules exprimant des anticorps et procédés de traitement les utilisant
US20210180059A1 (en) 2017-11-16 2021-06-17 Astrazeneca Ab Compositions and methods for improving the efficacy of cas9-based knock-in strategies
US20190153409A1 (en) 2017-11-17 2019-05-23 Aviv MedTech Ltd. Compositions comprising particles and methods for treating cancer
US20210187018A1 (en) 2017-12-07 2021-06-24 Flagship Pioneering Innovations V, Inc. Cytobiologics and therapeutic uses thereof
EP3724232A4 (fr) 2017-12-14 2021-12-15 The University of Ottawa Encapsulation d'exosomes et autophagie ciblée
EP3727467A4 (fr) 2017-12-22 2021-12-01 Centivax, Inc. Compositions du complexe majeur d'histocompatibilité (cmh) et procédés d'utilisation correspondants
CN115925943A (zh) 2017-12-27 2023-04-07 信达生物制药(苏州)有限公司 抗pd-l1抗体及其用途
EA202091134A1 (ru) 2017-12-28 2020-11-20 Кодиак Байосайенсес, Инк. Экзосомы для иммуноонкологической и противовоспалительной терапии
WO2019161192A1 (fr) 2018-02-15 2019-08-22 North Carolina State University Nanovésicules modifiées en tant que blocage de point de contrôle pour l'immunothérapie anticancéreuse
WO2019169141A1 (fr) 2018-02-28 2019-09-06 Lester Smith Medical Research Institute Production et utilisation de vésicules extracellulaires
AU2019232012A1 (en) 2018-03-08 2020-09-24 Rubius Therapeutics, Inc. Therapeutic cell systems and methods for treating cancer and infectious diseases
US20210060052A1 (en) 2018-03-15 2021-03-04 Atossa Therapeutics, Inc. In situ methods of inducing of immune response
US20200362052A1 (en) 2018-04-02 2020-11-19 Souvie Biodelivery, LLC Compositions and methods for treating toll-like receptor-driven inflammatory diseases
US20210023219A1 (en) 2018-04-06 2021-01-28 North Carolina State University Cell assembly-mediated delivery of checkpoint inhibitors for cancer immunotherapy
CA3096938A1 (fr) 2018-04-10 2019-10-17 Ottawa Hospital Research Institute Compositions a base de microarn et procedes utilises dans le traitement de maladies
US11413315B2 (en) 2018-04-29 2022-08-16 City Of Hope Neural stem cell-mediated cancer treatment
WO2019213706A1 (fr) 2018-05-08 2019-11-14 Deakin University Administration de médicament basée sur des vésicules extracellulaires
US20210213056A1 (en) 2018-05-09 2021-07-15 Children's Medical Center Corporation Mesenchymal stromal cell exosome-treated monocytes and uses thereof
EP3802578A4 (fr) 2018-06-01 2022-03-23 Washington University Suppression du syndrome de libération des cytokines lors d'une thérapie cellulaire par récepteur antigénique chimérique
US11505782B2 (en) 2018-06-04 2022-11-22 Calidi Biotherapeutics, Inc. Cell-based vehicles for potentiation of viral therapy
EP3801584B1 (fr) 2018-06-04 2023-09-27 Calidi Biotherapeutics, Inc. Véhicules à base de cellules pour la potentialisation d'une thérapie virale
MX2020013901A (es) 2018-06-19 2021-05-27 H Lee Moffitt Cancer Ct & Res Virus oncolítico o antígeno que presenta terapia contra el cáncer mediada por células usando interferón tipo i y lingado de cd40.
EP3810192A1 (fr) 2018-06-22 2021-04-28 Vyriad Méthodes de traitement du cancer par polythérapie
EP3823639A4 (fr) 2018-07-18 2022-07-20 Exostem Biotec Ltd. Immunothérapie à base d'exosomes et de msc
BR112021001117A2 (pt) 2018-07-22 2021-04-20 Health Research, Inc. células cancerígenas modificadas, composição farmacêutica, linha celular, métodos para fazer células cancerígenas modificadas e para estimular uma resposta imune, vetor de expressão isolado ou combinação de vetores de expressão isolados, e, uma ou mais células cancerígenas modificadas
US20220340898A1 (en) 2018-08-01 2022-10-27 Yale University Compositions and Methods for Identification of Membrane Targets for Enhancement of T cell Activity Against Cancer
US20220081691A1 (en) 2018-08-07 2022-03-17 Dana-Farber Cancer Institute, Inc Modulating ptpn2 to increase immune responses and perturbing gene expression in hematopoietic stem cell lineages
US20220000971A1 (en) 2018-08-24 2022-01-06 Transfert Plus, S.E.C. Methods and compounds for targeting sortilin receptors and inhibiting vasculogenic mimicry
WO2020049158A1 (fr) 2018-09-07 2020-03-12 Astrazeneca Ab Compositions et procédés pour des nucléases améliorées
AU2019351274A1 (en) 2018-09-27 2021-05-27 Genocea Biosciences, Inc. Treatment methods
KR20210091137A (ko) 2018-09-27 2021-07-21 제노세아 바이오사이언스, 인코퍼레이티드 치료 방법
US20200215114A1 (en) 2018-11-19 2020-07-09 Exosome Therapeutics, Inc. Compositions and methods for producing exosome loaded therapeutics for the treatment of multiple oncological disorders
EP3876951A1 (fr) 2018-11-06 2021-09-15 Calidi Biotherapeutics, Inc. Systèmes améliorés pour thérapie virale oncolytique à médiation cellulaire
WO2020205579A1 (fr) 2019-03-29 2020-10-08 University Of Southern California Exosomes génétiquement modifiés pour la modulation immunitaire
CA3133410A1 (fr) 2019-04-25 2020-10-29 Dcprime B.V. Methode de vaccination anti-tumorale
EP4022074A4 (fr) 2019-08-27 2023-11-15 The Trustees of Columbia University in the City of New York Exosomes modifiés pour une administration ciblée
JP2023515355A (ja) * 2020-02-11 2023-04-13 サイトナス セラピューティクス，インク． 高速ワクチンプラットフォーム

Also Published As

Publication number Publication date
US20210162038A1 (en) 2021-06-03
GB2597623A (en) 2022-02-02
US11674121B2 (en) 2023-06-13
JP2022184879A (ja) 2022-12-13
US10927349B2 (en) 2021-02-23
US20200216814A1 (en) 2020-07-09
US20230212520A1 (en) 2023-07-06
GB2578394A (en) 2020-05-06
KR20220124817A (ko) 2022-09-14
US20210189345A1 (en) 2021-06-24
JP7510467B2 (ja) 2024-07-03
US11248213B2 (en) 2022-02-15
GB202000541D0 (en) 2020-02-26
CN111491655A (zh) 2020-08-04
WO2019032628A1 (fr) 2019-02-14
US20220177847A1 (en) 2022-06-09
US20220204938A1 (en) 2022-06-30
KR20200037353A (ko) 2020-04-08
US10947507B2 (en) 2021-03-16
US20200368287A1 (en) 2020-11-26
US20200368285A1 (en) 2020-11-26
GB202115748D0 (en) 2021-12-15
EP3664830A1 (fr) 2020-06-17
AU2018316166A1 (en) 2020-02-06
US20230159897A1 (en) 2023-05-25
EP3664830A4 (fr) 2020-07-01
JP2020530454A (ja) 2020-10-22

Similar Documents

Publication Publication Date Title
US10927349B2 (en) Platform for generating safe cell therapeutics
US10960071B2 (en) Platform for generating safe cell therapeutics
Ikemoto et al. Autologous transplantation of SM/C-2.6+ satellite cells transduced with micro-dystrophin CS1 cDNA by lentiviral vector into mdx mice
Wagner et al. Fate of intravenously injected mesenchymal stem cells and significance for clinical application
Cuchiara et al. Bioactive poly (ethylene glycol) hydrogels to recapitulate the HSC niche and facilitate HSC expansion in culture
US12018080B2 (en) Methods and compositions for treating cancer by targeting the CLEC2D-KLRB1 pathway
HUE033392T2 (en) Immunomodulation Progenior (IMP) cell
US20220025403A1 (en) Reduced and minimal manipulation manufacturing of genetically-modified cells
Budgude et al. Mesenchymal stromal cell‐derived extracellular vesicles as cell‐free biologics for the ex vivo expansion of hematopoietic stem cells
US20230015661A1 (en) Methods and use for bioengineering enucleated cells
US12049644B2 (en) Platform for generating safe cell therapeutics
Nie et al. DNA nanodevice as a multi-module co-delivery platform for combination cancer immunotherapy
WO2024107723A2 (fr) Système de délivrance de nanovésicules biomimétiques hypoimmunogènes pour des maladies associées à la lymphohistiocytose hémophagocytaire (lhh)
Wang et al. Enucleated human mesenchymal stromal cells for the homing and the delivery of therapeutic cargos in vivo
WO2023081733A1 (fr) Compositions et méthodes de traitement anticancéreux

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220831

EEER Examination request

Effective date: 20220831

EEER Examination request

Effective date: 20220831

EEER Examination request

Effective date: 20220831

EEER Examination request

Effective date: 20220831